Providing Answers, Support and Hope in Kansas, Missouri, and Central & Southern Illinois
This is my chapter |
Reset
Biogen Inc. announced today that its Phase 2 LILAC study captured positive top-line results for investigational drug, BIIB059. The drug demonstrated statistically significant reduction of disease activity in people with cutaneous lupus (CLE) and systemic lupus erythematosus (SLE) compared to those who received placebo.
The drug is a monoclonal antibody that blocks BDCA2 cells which inhibit the production of major inflammatory mediators in lupus. The Phase 2 LILAC study was a two-part, randomized, double blind, placebo-controlled study that enrolled 264 individuals. The safety and tolerability profile of BIIB059 supports its continued development. The drug continues to be researched in SLE and CLE.
BIIB059 shows promise as a new treatment option. Continue to follow the Lupus Foundation of America for updates on BIIB059 and learn more about medications used to treat lupus.
Lupus Foundation of America, Heartland Region
8050 Watson Road
Suite 169
St. Louis, MO 63119
314.644.2222
infomidwest@lupus.org
There are multiple chapters near you. Select your preferred chapter.
Supporting lupus patients and advocates in Arizona.
Serving the District of Columbia, Maryland, and Northern Virginia.
Serving Kansas, Missouri, and Central & Southern Illinois
Serving north, central and west Texas, including Dallas/Fort Worth, San Antonio, Austin, El Paso, Lubbock, and surrounding areas
Serving Northern Illinois, Indiana, Iowa, Michigan, and Minnesota
Serving Connecticut, Massachusetts, Maine, New Hampshire, northern and central New Jersey, New York, Rhode Island, and Vermont
Serving Pennsylvania, Delaware and Southern New Jersey
Serving Houston, Beaumont, Corpus Christi, Harlingen and surrounding areas in Texas
There are multiple walks near you.
This website uses cookies to ensure you get the best experience. Learn more